

Edyta Maria Urbanska

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4587661/publications.pdf>

Version: 2024-02-01

13
papers

231
citations

1478280

6
h-index

1281743

11
g-index

14
all docs

14
docs citations

14
times ranked

406
citing authors

#	ARTICLE	IF	CITATIONS
1	Durable Response to Combined Osimertinib and Pralsetinib Treatment for Osimertinib Resistance Due to Novel Intergenic <i>ANK3-RET</i> Fusion in <i>EGFR</i> -Mutated Non-Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2022, , .	1.5	7
2	Intracranial Response of ALK+ Non-Small-cell Lung Cancer to Second-line Dose-escalated Brigatinib After Alectinib Discontinuation Due to Drug-induced Hepatitis and Relapse After Whole Brain Radiotherapy Followed by Stereotactic Radiosurgery. <i>Clinical Lung Cancer</i> , 2021, 22, e528-e532.	1.1	8
3	Uncommon Presentation of Granulomatosis with Polyangiitis Mimicking Metastatic Lung Cancer. <i>Clinics and Practice</i> , 2021, 11, 293-302.	0.6	3
4	P46.03 Targeting ROS1 Gene Rearrangement by Crizotinib as Neoadjuvant Treatment Before Definitive Radiotherapy in Locally Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, S1094.	0.5	1
5	P10.06 Affiliation to the Labour Market in Denmark for Patients Under 60 Years of Age After Diagnosis and Treatment for ALK-Positive NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, S1000-S1001.	0.5	0
6	P46.02 Impact of Real-World DNA- and RNA-Based Rebiopsy Testing in <i>EGFR</i> -Mutated NSCLC Progressing on Osimertinib. <i>Journal of Thoracic Oncology</i> , 2021, 16, S1093-S1094.	0.5	1
7	Treatment Algorithm for Advanced ALK-Rearranged NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, e156-e157.	0.5	2
8	Changing ALK-TKI-Resistance Mechanisms in Rebiopsies of ALK-Rearranged NSCLC: ALK- and BRAF-Mutations Followed by Epithelial-Mesenchymal Transition. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2847.	1.8	25
9	Intrinsic resistance to <i>EGFR</i> -Tyrosine Kinase Inhibitors in <i>EGFR</i> -Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance. <i>Cancers</i> , 2019, 11, 923.	1.7	124
10	P3.08-18 Changing Resistance Mechanisms in Rebiopsies of ALK-Positive NSCLC During Multiple Lines of Therapy: ALK/BRAF-Mutations Followed By EMT. <i>Journal of Thoracic Oncology</i> , 2018, 13, S946.	0.5	1
11	Heterogeneous resistance mechanisms in an <i>EGFR</i> exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent <i>FGFR3</i> -mutation, localized transformation to <i>EGFR</i> -mutated SCLC, and acquired T790M <i>EGFR</i> -mutation. <i>Lung Cancer</i> , 2017, 113, 14-17.	0.9	20
12	P3.01-007 Heterogeneous Resistance Mechanisms in Rebiopsies from <i>EGFR</i> -Mutated NSCLC: Transformation to SCLC; <i>FGFR3</i> and T790M Mutations. <i>Journal of Thoracic Oncology</i> , 2017, 12, S2203.	0.5	0
13	Concomitant occurrence of <i>EGFR</i> (epidermal growth factor receptor) and <i>KRAS</i> (V-Ki-ras2 Kirsten rat Tj ET) Q11R mutation in a non-small cell lung adenocarcinoma patient with acquired resistance to crizotinib: a case report. <i>BMC Research Notes</i> , 2013, 6, 489.	0.6	39